Press Releases

REDWOOD CITY, Calif. – Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today the appointment of Norman M. Greenberg, Ph.D., as Chief Scientific Officer. Dr. Greenberg brings to Atreca over 25 years of experience conducting pioneering research and advancing innovative cancer immunotherapies in the clinic. In his new role, Dr. Greenberg will report to Tito A. Serafini, Ph.D., Atreca’s President, Chief Executive Officer, and Co-Founder, and his appointment is effective immediately.

“Norm has played a pivotal role in the success of cancer immunotherapy, with his research efforts having provided essential groundwork for the first drug of the checkpoint inhibitor class to reach the market,” commented Dr. Serafini. “Furthermore, during his time in industry, he was directly responsible for discovering and developing multiple immuno-oncology therapeutics, including several currently in advanced clinical trials. He joins Atreca at a seminal moment as we continue to progress our lead programs. I am very pleased to have someone of Norm’s stature and accomplishment join our growing leadership team.”

Prior to joining Atreca, Dr. Greenberg was Senior Vice President of Translational Research at Checkmate Pharmaceuticals, where he was responsible for advancing novel immuno-oncology combination therapeutics in clinical trials. Previously, he served as Vice President of Global Research, Oncology, at MedImmune (the biologics arm of AstraZeneca), where he spearheaded global research activities for immune-mediated and tumor-targeted therapies, a number of which are advancing in the clinic. Dr. Greenberg also played key roles during scientific due diligence preceding the acquisitions of Spirogen and Amplimmune. Prior to this, he was the Senior Director of Research, Oncology, at Pfizer, where he led the company’s specialized disease group to develop novel small molecule and biologic drugs for unmet needs in breast, ovarian, and prostate cancers. Before joining industry, Dr. Greenberg was a Full Member in the Clinical Research Division at the Fred Hutchinson Cancer Research Center, where his team investigated the molecular mechanisms of tumor initiation, progression, and metastasis. He began his career at Baylor College of Medicine where, as a tenured Associate Professor in Molecular and Cellular Biology, he created sophisticated animal models to help advance the understanding of how immune checkpoint regulators such as CTLA4 could be applied in the clinic. Dr. Greenberg received his B.Sc. degree in Microbiology and Immunology from the University of Toronto and his Ph.D. degree in Microbiology and Immunology from the University of British Columbia.

Dr. Greenberg stated, “I am very excited to join the dedicated and highly talented scientists and engineers at Atreca to further advance its R&D programs, based on the Company’s industry-leading Immune Repertoire Capture™ technology platform. As IRC™ has demonstrated a unique capacity to fully characterize a patient’s successful immune responses to cancer, I believe this technology has the potential to hasten new paradigms and approaches to meet the persistent and compelling needs in cancer care.”

About Atreca, Inc.
Atreca is a privately held biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-cancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atreca’s proprietary Immune Repertoire Capture™ technology profiles a patient’s immune response at the single-cell level at very high throughput without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates with the objective of enhancing engagement of the human immune response in cancer treatment and other indications, thus optimizing therapeutic outcomes. For more information on Atreca, please visit www.atreca.com.